Celcuity reports strong early commercial launch of Revtorpic in Q3 2026
FROM THE WIRE · FINANCE.YAHOO.COM
This article first appeared on GuruFocus. Release Date: November 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Strong early commercial launch: 78% of top 36 strategic accounts ordered Revtorpic…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishEarly uptake and broad payer coverage support the commercial outlook for the lead product.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 0178% of the top 36 strategic accounts ordered Revtorpic within the first month.
- 0291% of US commercial and Medicare lives have coverage.
- 03Estimated annual US market of 9 billion dollars.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets